UnitedHealth shares are doing something unusual ahead of earnings

UnitedHealth reports earnings Tuesday with options implying a 6.5% earnings move and 40% volatility versus roughly 20% realized volatility; the stock has fallen in five of its past eight earnings reactions. Management's 13%–16% EPS growth target is described as achievable, while declining ACA marketplace enrollment and rising healthcare costs are headwinds; Commercial fee-based enrollment grew about 2.9% year over year and Medicare enrollment rose 4.5%. The article proposes selling November 340/420 options to help fund a January 2027 400 call, reducing its $18.20 cost to a net debit of about $7.60, with downside exposure below $340.

Analysis

The apparent volatility premium is not automatically a sell: realized volatility understates discrete earnings-gap risk, and UNH’s history of large post-report moves is evidence that the distribution has fat tails. The proposed structure is not simply a cheaper long call. Below $340 at November expiry, the short put creates a 100-share purchase obligation per contract; the stated $347.60 effective basis assumes assignment and does not cap losses if the shares fall further. Above $420, the January call is not a same-expiry hedge for the November short call: assignment can leave a short-stock position and financing/mark-to-market exposure that must be actively managed, even if the longer-dated call has intrinsic value.

Fundamentally, enrollment is a weak proxy for earnings quality. ACA attrition may be offset by Medicare and employer growth, but worsening utilization or unfavorable pricing can overwhelm membership gains through medical costs and underwriting margins. A reported growth target is therefore less informative than cost trends and guidance on margins. Near term, earnings and any medical-cost outlook revision dominate; over 1–3 months, enrollment mix, utilization and policy/pricing updates matter. Over 6–18 months, sustained cost pressure or Medicare-rate changes could challenge the recovery case. The contrarian risk is that low-looking valuation and cash-flow yield may be a value trap if earnings estimates are still adjusting; conversely, a clean cost trend could prompt multiple recovery. Treat the options premium as compensation for tail exposure, not proof that volatility is mispriced.

Key Decisions for Investors

• Do not put on the cited November 340/420 strangle plus January 2027 call mechanically ahead of earnings. If using it, size the short put as a willingness and capacity to own 100 UNH shares per contract at $340, and plan in advance for assignment or early management of the November call.
• For bullish exposure with defined downside, prefer a January 2027 call spread or a smaller outright call position over financing it with an uncapped short put; enter after the earnings gap if implied volatility contracts and the cost trend remains consistent with guidance.
• Use the report to test medical-cost trend, underwriting-margin direction, and forward EPS guidance against enrollment growth. A cost deterioration or guidance cut falsifies the recovery thesis; stable costs and maintained guidance would support adding exposure after the event.
• Watch broader managed-care peers, including CVS, Elevance Health and Cigna, for confirmation or divergence in utilization and pricing pressure; do not assume UNH enrollment gains translate into sector-wide profitability.